Entrada Therapeutics Inc (TRDA)
12.45
+0.09
(+0.73%)
USD |
NASDAQ |
Apr 26, 16:00
12.68
+0.22
(+1.81%)
After-Hours: 20:00
Entrada Therapeutics Free Cash Flow (Quarterly): -4.989M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -4.989M |
| September 30, 2023 | -25.94M |
| June 30, 2023 | -36.61M |
| March 31, 2023 | 201.73M |
| December 31, 2022 | -28.01M |
| September 30, 2022 | -28.29M |
| Date | Value |
|---|---|
| June 30, 2022 | -18.78M |
| March 31, 2022 | -21.58M |
| December 31, 2021 | -21.86M |
| September 30, 2021 | -14.88M |
| June 30, 2021 | -9.454M |
| March 31, 2021 | -9.244M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-36.61M
Minimum
Jun 2023
201.73M
Maximum
Mar 2023
-1.494M
Average
-20.18M
Median
Free Cash Flow (Quarterly) Benchmarks
| GlycoMimetics Inc | -7.616M |
| Lyell Immunopharma Inc | -40.66M |
| Candel Therapeutics Inc | -7.469M |
| Eliem Therapeutics Inc | -0.947M |
| NovaBay Pharmaceuticals Inc | -0.316M |